热门资讯> 正文

Theriva Biologics GAAP每股收益为-6.81美元

2024-11-12 21:24

Theriva Biologics press release (NYSE:TOVX): Q3 GAAP EPS of -$6.81.
Cash and cash equivalents totaled $16.4 million as of September 30, 2024, compared to $23.2 million as of December 31, 2023.

More on Theriva Biologics

Theriva Biologics up on positive DSMC review in SYN-004 trial for transplant recipients
Seeking Alpha’s Quant Rating on Theriva Biologics
Historical earnings data for Theriva Biologics
Financial information for Theriva Biologics

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。